Agenus | AGEN - Gross Profit On Sales


Agenus reported $34.2M in Gross Profit on Sales for its fiscal quarter ending in December of 2025.





Gross Profit On Sales Change Date
AbbVie USD 10.47B 605M Sep/2025
Agenus USD 34.2M 4.61M Dec/2025
Amgen USD 6.48B 307M Sep/2025
AstraZeneca USD 12.39B 5M Dec/2025
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Celldex Therapeutics USD 121K 609K Dec/2025
CSL USD 4.46B 2.71B Dec/2025
Eli Lilly USD 14.59B 1.48B Sep/2025
Gilead Sciences USD 6.31B 106M Dec/2025
GlaxoSmithKline GBP 6.18B 106M Dec/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Incyte USD 1.39B 118.68M Dec/2025
Intrexon USD -297K 167K Jun/2024
J&J USD 16.6B 118M Dec/2025
Jiangsu Hengrui CNY 6.36B 1.15B Sep/2025
Karyopharm Therapeutics USD 32.6M 63.38M Dec/2025
MacroGenics USD 31.11M 30.14M Dec/2025
Merck EUR 2.96B 252M Dec/2025
Merck USD 13.42B 431M Sep/2025
Novartis USD 10.25B 570M Dec/2025
Novavax USD 125.04M 76.09M Dec/2025
Pfizer USD 3.54B 7.61B Sep/2025
Regeneron Pharmaceuticals USD 3.3B 67M Dec/2025
Rigel Pharmaceuticals USD 28.49M 7.01M Jun/2024
Sangamo BioSciences -2.39M 1.09M Jun/2024
Veracyte USD 101.97M 10.69M Dec/2025